Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01649297




Registration number
NCT01649297
Ethics application status
Date submitted
23/07/2012
Date registered
25/07/2012
Date last updated
23/07/2015

Titles & IDs
Public title
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Scientific title
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Secondary ID [1] 0 0
2012-000905-53
Secondary ID [2] 0 0
1276.10
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - empagliflozin (low dose qd)
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Empagliflozin (high dose qd)
Treatment: Drugs - empagliflozin (high dose bid)
Treatment: Drugs - Placebo
Treatment: Drugs - empagliflozin (low dose bid)

Experimental: empagliflozin (high dose qd) - Patients receive Empagliflozin high dose once daily

Experimental: empagliflozin (high dose bid) - Patients receive Empagliflozin high dose split twice daily

Experimental: empagliflozin (low dose qd) - Patients receive Empagliflozin low dose once daily

Experimental: empagliflozin (low dose bid) - Patients receive Empagliflozin low dose split twice daily

Placebo Comparator: Placebo - Patients receive placebo matching Empagliflozin


Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose qd)

Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose bid)

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose qd)

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose qd)

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose qd)

Treatment: Drugs: empagliflozin (low dose qd)
Patients receive Empagliflozin low dose once daily

Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose qd)

Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose bid)

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose bid)

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose bid)

Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose qd)

Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose bid)

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose bid)

Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose qd)

Treatment: Drugs: Placebo
Patients receive placebo matching empagliflozin (low dose bid)

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose bid)

Treatment: Drugs: Empagliflozin (high dose qd)
Patients receive Empagliflozin high dose once daily

Treatment: Drugs: empagliflozin (high dose bid)
Patients receive Empagliflozin high dose split twice daily

Treatment: Drugs: Placebo
Patients receive placebo matching Empagliflozin (high dose qd)

Treatment: Drugs: empagliflozin (low dose bid)
Patients receive Empagliflozin low dose split twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16
Timepoint [1] 0 0
Baseline and 16 weeks
Secondary outcome [1] 0 0
Fasting Plasma Glucose (FPG) Change From Baseline at Week 16
Timepoint [1] 0 0
Baseline and 16 weeks

Eligibility
Key inclusion criteria
Inclusion criteria:

1. confirmed diagnosis of T2DM

2. Glycated hemoglobin (HbA1c) >=7.0 and <=10/0% at Visit 1

3. Metformin therapy (at least 1500 mg/day, BID)

4. age>=18 at Visit 1

5. body mass index <=45 kg/m2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. estimated creatinine clearance rate (eCCr) <60 ml/min (Cockcroft-Gault formula)
screening and/or run-in

2. a confirmed glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during
placebo run-in

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2013
Sample size
Target
Accrual to date
Final
983
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
1276.10.61002 Boehringer Ingelheim Investigational Site - Wollongong
Recruitment hospital [2] 0 0
1276.10.61001 Boehringer Ingelheim Investigational Site - Box Hill
Recruitment postcode(s) [1] 0 0
- Wollongong
Recruitment postcode(s) [2] 0 0
- Box Hill
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maine
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Mississippi
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
British Columbia
Country [22] 0 0
Canada
State/province [22] 0 0
Manitoba
Country [23] 0 0
Canada
State/province [23] 0 0
New Brunswick
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
Estonia
State/province [26] 0 0
Pärnu
Country [27] 0 0
Estonia
State/province [27] 0 0
Tallinn
Country [28] 0 0
Estonia
State/province [28] 0 0
Viljandi County
Country [29] 0 0
France
State/province [29] 0 0
Aire sur l'Adour
Country [30] 0 0
France
State/province [30] 0 0
Bischheim
Country [31] 0 0
France
State/province [31] 0 0
Bourg des Comptes
Country [32] 0 0
France
State/province [32] 0 0
Bourges
Country [33] 0 0
France
State/province [33] 0 0
Broglie
Country [34] 0 0
France
State/province [34] 0 0
Mont de Marsan
Country [35] 0 0
France
State/province [35] 0 0
Paris
Country [36] 0 0
France
State/province [36] 0 0
Saint Vinecnt de Tyrosse
Country [37] 0 0
France
State/province [37] 0 0
Segre
Country [38] 0 0
France
State/province [38] 0 0
Strasbourg
Country [39] 0 0
Georgia
State/province [39] 0 0
Tbilisi
Country [40] 0 0
Germany
State/province [40] 0 0
Aschaffenburg
Country [41] 0 0
Germany
State/province [41] 0 0
Berlin
Country [42] 0 0
Germany
State/province [42] 0 0
Essen
Country [43] 0 0
Germany
State/province [43] 0 0
Frankfurt
Country [44] 0 0
Germany
State/province [44] 0 0
Nürnberg
Country [45] 0 0
Germany
State/province [45] 0 0
Rehlingen-Siersburg
Country [46] 0 0
Guatemala
State/province [46] 0 0
Guatemala Ciudad
Country [47] 0 0
Guatemala
State/province [47] 0 0
Quetzaltenango Ciudad
Country [48] 0 0
Italy
State/province [48] 0 0
Arenzano (GE)
Country [49] 0 0
Italy
State/province [49] 0 0
Bologna
Country [50] 0 0
Italy
State/province [50] 0 0
Catanzaro
Country [51] 0 0
Italy
State/province [51] 0 0
Napoli
Country [52] 0 0
Italy
State/province [52] 0 0
Palermo
Country [53] 0 0
Italy
State/province [53] 0 0
Roma
Country [54] 0 0
Italy
State/province [54] 0 0
Torino
Country [55] 0 0
Latvia
State/province [55] 0 0
Daugavpils
Country [56] 0 0
Latvia
State/province [56] 0 0
Ogre
Country [57] 0 0
Latvia
State/province [57] 0 0
Riga
Country [58] 0 0
Latvia
State/province [58] 0 0
Tukums
Country [59] 0 0
Lithuania
State/province [59] 0 0
Kaunas
Country [60] 0 0
Lithuania
State/province [60] 0 0
Klaipeda
Country [61] 0 0
Lithuania
State/province [61] 0 0
Vilnius
Country [62] 0 0
Mexico
State/province [62] 0 0
Ciudad de Mexico
Country [63] 0 0
Mexico
State/province [63] 0 0
Durango
Country [64] 0 0
Mexico
State/province [64] 0 0
Pachuca
Country [65] 0 0
Mexico
State/province [65] 0 0
Tijuana
Country [66] 0 0
New Zealand
State/province [66] 0 0
Christchurch
Country [67] 0 0
New Zealand
State/province [67] 0 0
Greenlane East Auckland NZ
Country [68] 0 0
Poland
State/province [68] 0 0
Bialystok
Country [69] 0 0
Poland
State/province [69] 0 0
Gizycko
Country [70] 0 0
Poland
State/province [70] 0 0
Katowice
Country [71] 0 0
Poland
State/province [71] 0 0
Krakow
Country [72] 0 0
Poland
State/province [72] 0 0
Warszawa
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Moscow
Country [74] 0 0
Russian Federation
State/province [74] 0 0
St. Petersburg
Country [75] 0 0
South Africa
State/province [75] 0 0
Paarl
Country [76] 0 0
South Africa
State/province [76] 0 0
Parow
Country [77] 0 0
South Africa
State/province [77] 0 0
Plumstead, Cape Town
Country [78] 0 0
South Africa
State/province [78] 0 0
Pretoria
Country [79] 0 0
South Africa
State/province [79] 0 0
Somerset West
Country [80] 0 0
Spain
State/province [80] 0 0
Barcelona
Country [81] 0 0
Spain
State/province [81] 0 0
L'Hospitalet de Llobregat
Country [82] 0 0
Spain
State/province [82] 0 0
Les Borges del Camp
Country [83] 0 0
Spain
State/province [83] 0 0
Sant Adria del Besos
Country [84] 0 0
Spain
State/province [84] 0 0
Vic
Country [85] 0 0
Ukraine
State/province [85] 0 0
Kharkiv
Country [86] 0 0
Ukraine
State/province [86] 0 0
Kiev
Country [87] 0 0
Ukraine
State/province [87] 0 0
Kyiv

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Eli Lilly and Company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The aim of this study is to investigate the efficacy and safety of two doses (high and low)
of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus
(T2DM) and insufficient glycaemic control. Both doses may be given once daily or split to a
twice daily dosage. This results in 4 different dosage regimens of empagliflozin (high dose
once daily or split vs. low dose once daily or split). This is done to evaluate whether a
twice daily dose regimen of empagliflozin results in a loss of efficacy relative to once
daily dosing when given on top of metformin background therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01649297
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01649297